Your browser doesn't support javascript.
loading
Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
Antosz, Kayla; Battle, Sarah; Chang, Jack; Scheetz, Marc H; Al-Hasan, Majdi; Bookstaver, P Brandon.
Afiliação
  • Antosz K; Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
  • Battle S; Prisma Health-Midlands, Columbia, South Carolina, USA.
  • Chang J; Prisma Health-Midlands, Columbia, South Carolina, USA.
  • Scheetz MH; Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
  • Al-Hasan M; Pharmacometrics Center of Excellence, Department of Pharmacy Practice, Midwestern University College of Pharmacy, Downers Grove, Illinois, USA.
  • Bookstaver PB; Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Pharmacotherapy ; 43(1): 85-95, 2023 01.
Article em En | MEDLINE | ID: mdl-36521869
ABSTRACT
Infections of the central nervous system (CNS) are complex to treat and associated with significant morbidity and mortality. Historically, antistaphylococcal penicillins such as nafcillin were recommended for the treatment of methicillin-susceptible staphylococcal CNS infections. However, the use of antistaphylococcal penicillins presents challenges, such as frequent dosing administration and adverse events with protracted use. This narrative reviews available clinical and pharmacokinetic/pharmacodynamic (PK/PD) data for cefazolin in CNS infections and produces a recommendation for use. Based on the limited available evidence analyzed, dose optimized cefazolin is likely a safe and effective alternative to antistaphylococcal penicillins for a variety of CNS infections due to methicillin-susceptible Staphylococcus aureus. Given the site of infection and wide therapeutic index of cefazolin, practitioners may consider dosing cefazolin regimens of 2 g IV every 6 h or a continuous infusion of 8-10 g daily instead of 2 g IV every 8 h to optimize PK/PD properties.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Infecções do Sistema Nervoso Central / Bacteriemia Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Pharmacotherapy Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Infecções do Sistema Nervoso Central / Bacteriemia Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Pharmacotherapy Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos